Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease

Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor

(2015) Damayanthi Devineni et al.   CLINICAL THERAPEUTICS

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1

(2015) Markku Laakso et al.   DIABETES CARE

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015

(2015) Yehuda Handelsman et al.   Endocrine Practice

Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025

(2015) Alexander Kainz et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

AACE Comprehensive Diabetes Management Algorithm 2013

(2015) Alan Garber et al.   Endocrine Practice

Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes

(2014) Luca De Nicola et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

(2014) Hala Yamout et al.   AMERICAN JOURNAL OF NEPHROLOGY

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Metformin in Patients With Type 2 Diabetes and Kidney Disease

(2014) Silvio E. Inzucchi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Chronic Kidney Disease in Diabetes

(2013) Philip McFarlane et al.   Canadian Journal of Diabetes

Appendix 1: Etiologic Classification of Diabetes Mellitus

(2013)   Canadian Journal of Diabetes

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment

(2013) István Kiss et al.   CLINICAL PHARMACOKINETICS

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Outcomes Associated with Nonconcordance to National Kidney Foundation Guideline Recommendations for Oral Antidiabetic Drug Treatments in Patients with Concomitant Type 2 Diabetes and Chronic Kidney Disease

(2013) Shih-Yin Chen et al.   Endocrine Practice

Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment

(2013) Yan-Ling He et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study

(2013) Anna Solini et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

(2013) Vlado Perkovic et al.   KIDNEY INTERNATIONAL

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

(2013) Donald E. Kohan et al.   KIDNEY INTERNATIONAL

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment

(2013) Anja Schweizer et al.   Diabetes Therapy

Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?

(2013) Felix Kulozik et al.   Therapeutic Advances in Endocrinology and Metabolism

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

(2012)   AMERICAN JOURNAL OF KIDNEY DISEASES

Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes

(2012) B. Detournay et al.   DIABETES & METABOLISM

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

(2012) J. C. Arjona Ferreira et al.   DIABETES CARE

A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency

(2012) D. Baldwin et al.   DIABETES CARE

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

(2012) J. B. McGill et al.   DIABETES CARE

One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Metformin therapy in patients with chronic kidney disease

(2012) J. K. Duong et al.   DIABETES OBESITY & METABOLISM

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area

(2012) Gabriel Coll-de-Tuero et al.   BMC Nephrology

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

(2011) David W. Boulton et al.   CLINICAL PHARMACOKINETICS

Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency

(2011) K. J. Lipska et al.   DIABETES CARE

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*

(2011) U. Graefe-Mody et al.   DIABETES OBESITY & METABOLISM

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

(2011) M. Nowicki et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

(2011) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

(2011) M. Nowicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?

(2011) Helen J. Nye et al.   NEPHRON CLINICAL PRACTICE

Type 2 Diabetes Mellitus and Renal Impairment in a Large Outpatient Electronic Medical Records Database: Rates of Diagnosis and Antihyperglycemic Medication Dose Adjustment

(2011) Juliana L. Meyers et al.   POSTGRADUATE MEDICINE

Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis

(2011) K. Shima et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Hemoglobin A1c and Fructosamine for Assessing Glycemic Control in Diabetic Patients With CKD Stages 3 and 4

(2010) Harn-Shen Chen et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Relationship between Assays of Glycemia in Diabetic Subjects with Advanced Chronic Kidney Disease

(2010) Barry I. Freedman et al.   AMERICAN JOURNAL OF NEPHROLOGY

Metformin Use and Mortality Among Patients With Diabetes and AtherothrombosisMetformin Use With Diabetes and Atherothrombosis

(2010) Ronan Roussel   ARCHIVES OF INTERNAL MEDICINE

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

(2010) Carol E. Koro et al.   CLINICAL THERAPEUTICS

Novel Assay of Metformin Levels in Patients With Type 2 Diabetes and Varying Levels of Renal Function: Clinical recommendations

(2010) A. Frid et al.   DIABETES CARE

The Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease

(2010) J. M. Ng et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2011

(2010)   DIABETES CARE

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

(2010) Faramarz Ismail-Beigi et al.   LANCET

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

(2009) Lisbeth V. Jacobsen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Cross-sectional Survey of Chronic Kidney Disease and Diabetic Kidney Disease in Japanese Type 2 Diabetic Patients at Four Urban Diabetes Clinics

(2009) Yuko Watanabe et al.   INTERNAL MEDICINE

Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system

(2009) Jean-Pierre Riveline et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Insulin therapy in renal disease

(2008) Pedro Iglesias et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

(2008) J. C. N. Chan et al.   DIABETES OBESITY & METABOLISM

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE